eShowcase: TCN e-Systems
Tool places sponsors in control of their patient recruitment programs with real-time data reporting
Tool places sponsors in control of their patient recruitment programs with real-time data reporting
BBK Worldwide (Newton, MA) has a new suite of recruitment tools that are flexible and customizable for individual trial needs. TCN e-Systems produces real-time data designed to maximize clients' recruitment programs and cut enrollment times.
The main features of TCN e-Systems include: enrollment projection modeling; real-time tracking of recruitment tactics, inquiries, and referrals; accurate measurement of site and CRO performance; and control of clinical trial costs. The solution is applicable whether sponsors want to manage and/or deploy efforts for an entire therapeutic category, a specific protocol, or a single clinical study site. TCN e-Systems is comprised of six modules: Study Forecaster, Site Organizer, Patient Generator, Study Materials & Approval Tracker, Retention & Compliance, and Study Message Center.
BBK Worldwide, (617) 630-4477, www.bbkworldwide.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
